Please login to the form below
JAK inhibitor
This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.
FDA approves Incyte’s Opzelura for vitiligo
It is also the only topical formulation of a Janus kinase (JAK) inhibitor approved in the US. ... An over-activity of the JAK signalling pathway is thought to further drive inflammation involved in the progression of vitiligo.
Latest news
-
Eli Lilly and Incyte's Olumiant approved by FDA for hospitalised COVID-19 patients
This is the first and only FDA-approved Janus kinase (JAK) inhibitor for the treatment of hospitalised COVID-19 patients.
-
EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19, with remdesivir remaining the
-
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
plus Merck &Co’s checkpoint inhibitor Keytruda for the first-line treatment of advanced renal cell carcinoma (RCC). ... Pfizer’s Janus kinase (JAK) inhibitor Xeljanz also grew by 18% operationally, with a 16% growth in the US and a 21% increase in
-
Lilly reports positive data from its phase 3 ulcerative colitis trial
The IL-23 inhibitor also met all key secondary endpoints compared to placebo at week 12, including reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission and improvement in endoscopic histologic ... Mirikizumab also reduced
-
Researchers use AI to identify drugs that could be repurposed for Alzheimer’s
Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... Following this initial screening stage, the analysis produced a ranked list of candidates, which included several anti-inflammatory drugs in the Januse kinase (JAK
More from news
Approximately 6 fully matching, plus 86 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
The decade-long $5.1bn alliance, announced in July, came on the heels of a long relationship between the two companies that had already yielded a late-stage candidate, JAK inhibitor ... and filgotinib’s anticipated launch this year meets expectations
-
20 for 2020 – Five pharma companies to watch
AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite ... checkpoint
-
Drug launches to watch in 2019
These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... t the only oral JAK inhibitor developer with its eye on that particular prize.
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for
-
Deal Watch table for December 2014
Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors, and the latest ‘game changer’ Tyrosine kinase 2 (TYK2) inhibitors.
-
Fishawack Health
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor.
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Achieving communication excellence by targeting the right channel at the right time
- Environment: where does the pharmaceutical industry stand?
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- Novartis reports death of two patients treated with Zolgensma
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
Viseven
Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
